Author

Zahra Mesrizadeh

University of California San Diego

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioinformatics· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:statistical model· 4 Research Focus:cell type annotation· 3 Assay:spatial transcriptomics· 3 Research Focus:clustering· 2 Research Focus:differential expression· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

Kavitha MukundiD· 5 shared Shankar SubramaniamiD· 5 shared Jerneja TomšičiD· 3 shared Jovanny ZabaletaiD· 3 shared Lucio MieleiD· 3 shared Augusto C. OchoaiD· 2 shared David Eugene FrankhouseriD· 2 shared Luis Del ValleiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

Kavitha MukundORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Spatially resolved tumor-microenvironment architecture defines therapeutic response in unresectable hepatoblastoma

Zahra Mesrizadeh, Mylarappa Ningappa, Sarangarajan Ranganathan, Kavitha Mukund, Catherine Gestrich, Julia Meade, Judy Hereford Squires, Lori A. Schmitt, George Vincent Mazariegos, Marcus Malek, Chethan Ashokkumar, William A. MacDonald, Paul Morgan, Shankar Subramaniam, Rakesh Sindhi

This study identifies spatial tumor-microenvironment architectures in hepatoblastoma that correlate with therapeutic response using spatial transcriptomics and single-cell imaging.

bioRxiv · Oct 13, 2026 · PreprintCancer Biology

Spatial context of cellular heterogeneity in triple-negative breast cancer reveals actionable subtypes

Zahra Mesrizadeh, Kavitha Mukund, Lu Yang, Raju K. Pillai, David Eugene Frankhouser, Daniel Schmolze, Susan L. Neuhausen, Jovanny Zabaleta, Luis Del Valle, Jerneja Tomšič, Yuan Chun Ding, A. Matas Ochoa, Lucio Miele, Victoria Seewaldt, Shankar Subramaniam

The paper identifies three TNBC subtypes based on spatial transcriptomics and cellular mapping, revealing distinct tumor microenvironment architectures and potential therapeutic targets.

bioRxiv · Oct 13, 2026 · PreprintCancer Biology

Differential peripheral immune dynamics underlie therapeutic response to chemotherapy and chemo-immunotherapy in triple-negative breast cancer

Zahra Mesrizadeh, Kavitha Mukund, Shankar Subramaniam

The paper identifies distinct immune states in TNBC patients based on treatment and response, linking peripheral immune dynamics to therapeutic outcomes.

ImmunoHorizons · Sep 1, 2026Peer-reviewedBioinformatics

Spatially distinct cellular and molecular landscapes define prognosis in triple negative breast cancer

Kavitha Mukund, Darya Veraksa, David Eugene Frankhouser, Lixin Yang, Jerneja Tomšič, Raju K. Pillai, Srijan Atti, Zahra Mesrizadeh, Daniel D. Schmolze, Jovanny Zabaleta, Xiao‐Cheng Wu, Mary-Anne LeBlanc, Lucio Miele, Augusto C. Ochoa, Victoria L. Seewaldt, Shankar Subramaniam

This study uses spatial transcriptomics to identify molecular and cellular differences between good and poor prognosis triple-negative breast cancer subtypes, revealing distinct gene signatures that could inform therapy.

Cell Reports · Dec 31, 2025Peer-reviewedCancer Biology

A novel subtyping method for TNBC with implications for prognosis and therapy

Zahra Mesrizadeh, Kavitha Mukund, Jovanny Zabaleta, Luis Del Valle, Jerneja Tomšič, Susan L. Neuhausen, Yuan Chun Ding, Victoria L. Seewaldt, Augusto C. Ochoa, Lucio Miele, Shankar Subramaniam

This paper identifies three subtypes of TNBC based on transcriptomic profiles and cell-type composition, linking them to potential therapeutic targets and clinical outcomes.

bioRxiv · Jul 4, 2025 · PreprintBioinformatics